Lakefront Biotherapeutics NV (LKFT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Annual

0 400M 800M 1.2B 2021: 234.4M 2022: 241.2M 2023: 239.7M 2024: 275.6M 2025: 1.1B 2021 2022 2023 2024 2025

Gross Profit Annual

0 400M 800M 1.2B 2021: 232.8M 2022: 229.2M 2024: 240.8M 2025: 1.1B 2021 2022 2024 2025

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-300M -150M 0 150M 300M 450M 2021: -171.6M 2022: -131.1M 2023: -88.3M 2024: -188.3M 2025: 295M 2021 2022 2023 2024 2025

Net Income Annual

-300M -150M 0 150M 300M 450M 2021: -103.2M 2022: -218M 2023: 211.7M 2024: 74.1M 2025: 320.9M 2021 2022 2023 2024 2025

Cost of Revenue Annual

0 15M 30M 45M 2021: 1.6M 2022: 12.1M 2024: 34.9M 2025: 29.7M 2021 2022 2024 2025

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M 2021: -503.8M 2022: -500.5M 2023: -406M 2024: -320M 2025: -257.5M 2021 2022 2023 2024 2025

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M 2021: -558M 2022: -527.9M 2023: -424.7M 2024: -336.7M 2025: -271.2M 2021 2022 2023 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M 2021: 65.5M 2022: 65.7M 2023: 65.9M 2024: 65.9M 2025: 65.9M 2021 2022 2023 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.